Hair loss is a common side effect of Eribulin Mesylate. It could be reversible but the severity of hair loss varies from person to person. Consult your doctor if you have any concerns regarding hair loss.

Eribulin Mesylate is usually given on Days 1 and 8 of each recommended 21-day cycle. The duration of treatment varies from person to person. The number of cycles required for effective treatment will be decided by your doctor. Depending on the results of your blood tests, the doctor may need to delay administration of the medicine until the blood tests return to normal. If required, the doctor may also decide to reduce the dose you are given.

Eribulin Mesylate will be given to you by a doctor or healthcare professional as an injection into a vein, over a period of 2 to 5 minutes. The dose required will be decided based on your body surface area (expressed in square metres, or m2) which is calculated from your weight and height. The doctor may adjust the usual dose based on your blood test results or other factors. To ensure that the whole dose of Eribulin Mesylate is given, it is recommended that a saline solution is flushed into the vein after Eribulin Mesylate is given.

Eribulin Mesylate can cause serious side effects which include low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. It can also cause numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with Eribulin Mesylate and sometimes can be severe. It can cause harm to the baby when administered to a pregnant woman.

Women of childbearing age should use effective contraception during and up to 3 months after treatment with Eribulin Mesylate.It may cause serious birth defects and should not be used if you are pregnant unless it is thought clearly necessary after carefully considering all the risk to you and the baby.

Eribulin Mesylate should be handled carefully. Avoid any contact with skin, eyes, mouth and insides of nose. It is recommended to use gloves, goggles, and protective clothing while handling the medicine. If the skin comes into contact with the solution, it should be washed immediately and thoroughly with soap and water. Similarly, if your eyes, mouth or nose come in contact with Eribulin Mesylate, flush the area thoroughly with water. Pregnant staff should not handle Eribulin Mesylate.

Eribulin Mesylate may be diluted in up to 100 ml of sodium chloride 9 mg/ml (0.9%) solution and not in 5% dextrose. It should be given under the supervision of a physician experienced in giving cancer chemotherapy and should be administered by a health care professional only.